Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
BSX's Cash-to-Debt is ranked lower than
96% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. BSX: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
BSX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.16 Max: 4.69
Current: 0.03
0.03
4.69
Equity-to-Asset 0.39
BSX's Equity-to-Asset is ranked lower than
81% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. BSX: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
BSX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.51 Max: 0.83
Current: 0.39
0.18
0.83
Debt-to-Equity 0.81
BSX's Debt-to-Equity is ranked lower than
81% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 0.29 vs. BSX: 0.81 )
Ranked among companies with meaningful Debt-to-Equity only.
BSX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06  Med: 0.52 Max: 3.64
Current: 0.81
0.06
3.64
Interest Coverage 4.66
BSX's Interest Coverage is ranked lower than
92% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. BSX: 4.66 )
Ranked among companies with meaningful Interest Coverage only.
BSX' s Interest Coverage Range Over the Past 10 Years
Min: 0.37  Med: 1.92 Max: 4.66
Current: 4.66
0.37
4.66
Piotroski F-Score: 6
Altman Z-Score: 2.08
Beneish M-Score: -2.41
WACC vs ROIC
7.63%
10.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 12.36
BSX's Operating Margin % is ranked higher than
58% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. BSX: 12.36 )
Ranked among companies with meaningful Operating Margin % only.
BSX' s Operating Margin % Range Over the Past 10 Years
Min: -53.36  Med: -4.23 Max: 12.36
Current: 12.36
-53.36
12.36
Net Margin % 9.04
BSX's Net Margin % is ranked higher than
60% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. BSX: 9.04 )
Ranked among companies with meaningful Net Margin % only.
BSX' s Net Margin % Range Over the Past 10 Years
Min: -56.12  Med: -4.56 Max: 9.04
Current: 9.04
-56.12
9.04
ROE % 11.68
BSX's ROE % is ranked higher than
61% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. BSX: 11.68 )
Ranked among companies with meaningful ROE % only.
BSX' s ROE % Range Over the Past 10 Years
Min: -44.65  Med: -3.5 Max: 11.68
Current: 11.68
-44.65
11.68
ROA % 4.38
BSX's ROA % is ranked higher than
58% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. BSX: 4.38 )
Ranked among companies with meaningful ROA % only.
BSX' s ROA % Range Over the Past 10 Years
Min: -21.16  Med: -1.48 Max: 4.38
Current: 4.38
-21.16
4.38
ROC (Joel Greenblatt) % 60.05
BSX's ROC (Joel Greenblatt) % is ranked higher than
73% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. BSX: 60.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7  Med: -14.88 Max: 60.05
Current: 60.05
-144.7
60.05
3-Year Revenue Growth Rate 4.60
BSX's 3-Year Revenue Growth Rate is ranked lower than
51% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. BSX: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 4.6 Max: 29
Current: 4.6
-10.5
29
3-Year EBITDA Growth Rate 14.70
BSX's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. BSX: 14.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.1  Med: 14.7 Max: 271.1
Current: 14.7
-71.1
271.1
GuruFocus has detected 2 Warning Signs with Boston Scientific Corp $BSX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BSX's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

BSX Guru Trades in Q3 2016

Ray Dalio 50,900 sh (+425.61%)
John Paulson 410,000 sh (+336.17%)
Dodge & Cox 382,130 sh (-0.73%)
PRIMECAP Management 41,805,050 sh (-1.96%)
Mario Gabelli 673,046 sh (-2.14%)
Vanguard Health Care Fund 46,520,049 sh (-13.24%)
Steven Cohen 1,622,600 sh (-15.31%)
Paul Tudor Jones 26,610 sh (-21.72%)
Michael Price 700,000 sh (-22.22%)
Diamond Hill Capital 3,289,862 sh (-32.36%)
Pioneer Investments 1,878,761 sh (-36.59%)
Jim Simons 1,884,005 sh (-61.57%)
Eaton Vance Worldwide Health Sciences Fund 1,698,025 sh (-56.24%)
» More
Q4 2016

BSX Guru Trades in Q4 2016

Joel Greenblatt 99,384 sh (New)
David Tepper 550,000 sh (New)
Ray Dalio 91,000 sh (+78.78%)
Jim Simons 2,625,305 sh (+39.35%)
Pioneer Investments 1,941,017 sh (+3.31%)
Diamond Hill Capital 3,351,408 sh (+1.87%)
PRIMECAP Management 41,920,457 sh (+0.28%)
Michael Price 700,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Dodge & Cox 371,671 sh (-2.74%)
Mario Gabelli 653,146 sh (-2.96%)
Vanguard Health Care Fund 43,872,669 sh (-5.69%)
John Paulson 288,000 sh (-29.76%)
Steven Cohen 358,400 sh (-77.91%)
» More
Q1 2017

BSX Guru Trades in Q1 2017

Julian Robertson 900,000 sh (New)
Caxton Associates 20,100 sh (New)
Joel Greenblatt 1,664,082 sh (+1574.40%)
David Tepper 3,340,000 sh (+507.27%)
Jim Simons 5,726,705 sh (+118.13%)
Diamond Hill Capital 3,361,258 sh (+0.29%)
John Paulson Sold Out
Steven Cohen Sold Out
Ray Dalio Sold Out
Pioneer Investments 1,938,677 sh (-0.12%)
PRIMECAP Management 41,755,967 sh (-0.39%)
Vanguard Health Care Fund 42,272,393 sh (-3.65%)
Mario Gabelli 625,559 sh (-4.22%)
Dodge & Cox 328,655 sh (-11.57%)
Michael Price 500,000 sh (-28.57%)
» More
Q2 2017

BSX Guru Trades in Q2 2017

Steven Cohen 1,047,500 sh (New)
Eaton Vance Worldwide Health Sciences Fund 936,126 sh (New)
Julian Robertson 1,069,500 sh (+18.83%)
Pioneer Investments 1,974,820 sh (+1.86%)
PRIMECAP Management 42,369,167 sh (+1.47%)
Caxton Associates Sold Out
Dodge & Cox 324,255 sh (-1.34%)
Vanguard Health Care Fund 41,119,293 sh (-2.73%)
Jim Simons 5,305,605 sh (-7.35%)
Diamond Hill Capital 3,013,614 sh (-10.34%)
Mario Gabelli 551,059 sh (-11.91%)
David Tepper 2,264,900 sh (-32.19%)
Michael Price 295,000 sh (-41.00%)
Joel Greenblatt 24,597 sh (-98.52%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -2.73%0.06%$24.42 - $28.25 $ 28.698%41,119,293
David Tepper 2017-06-30 Reduce -32.19%0.44%$24.42 - $28.25 $ 28.698%2,264,900
Julian Robertson 2017-06-30 Add 18.83%0.92%$24.42 - $28.25 $ 28.698%1,069,500
Mario Gabelli 2017-06-30 Reduce -11.91%0.01%$24.42 - $28.25 $ 28.698%551,059
Dodge & Cox 2017-06-30 Reduce -1.34%$24.42 - $28.25 $ 28.698%324,255
Michael Price 2017-06-30 Reduce -41.00%0.63%$24.42 - $28.25 $ 28.698%295,000
Joel Greenblatt 2017-06-30 Reduce -98.52%0.52%$24.42 - $28.25 $ 28.698%24,597
Vanguard Health Care Fund 2017-03-31 Reduce -3.65%0.08%$21.88 - $25.41 $ 28.6918%42,272,393
David Tepper 2017-03-31 Add 507.27%1.14%$21.88 - $25.41 $ 28.6918%3,340,000
Joel Greenblatt 2017-03-31 Add 1574.40%0.5%$21.88 - $25.41 $ 28.6918%1,664,082
Julian Robertson 2017-03-31 New Buy4.22%$21.88 - $25.41 $ 28.6918%900,000
Mario Gabelli 2017-03-31 Reduce -4.22%$21.88 - $25.41 $ 28.6918%625,559
Michael Price 2017-03-31 Reduce -28.57%0.53%$21.88 - $25.41 $ 28.6918%500,000
Dodge & Cox 2017-03-31 Reduce -11.57%$21.88 - $25.41 $ 28.6918%328,655
John Paulson 2017-03-31 Sold Out 0.08%$21.88 - $25.41 $ 28.6918%0
Vanguard Health Care Fund 2016-12-31 Reduce -5.69%0.14%$20.09 - $23.77 $ 28.6931%43,872,669
Mario Gabelli 2016-12-31 Reduce -2.96%$20.09 - $23.77 $ 28.6931%653,146
David Tepper 2016-12-31 New Buy0.21%$20.09 - $23.77 $ 28.6931%550,000
Dodge & Cox 2016-12-31 Reduce -2.74%$20.09 - $23.77 $ 28.6931%371,671
John Paulson 2016-12-31 Reduce -29.76%0.03%$20.09 - $23.77 $ 28.6931%288,000
Joel Greenblatt 2016-12-31 New Buy0.03%$20.09 - $23.77 $ 28.6931%99,384
Vanguard Health Care Fund 2016-09-30 Reduce -13.24%0.35%$23.11 - $24.48 $ 28.6920%46,520,049
Michael Price 2016-09-30 Reduce -22.22%0.62%$23.11 - $24.48 $ 28.6920%700,000
Mario Gabelli 2016-09-30 Reduce -2.14%$23.11 - $24.48 $ 28.6920%673,046
John Paulson 2016-09-30 Add 336.17%0.08%$23.11 - $24.48 $ 28.6920%410,000
Dodge & Cox 2016-09-30 Reduce -0.73%$23.11 - $24.48 $ 28.6920%382,130
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:SYK, NYSE:EW, NYSE:ZBH, NAS:ALGN, NYSE:TFX, NYSE:VAR, NAS:ABMD, NAS:MASI, NAS:IART, NYSE:PEN, NAS:NUVA, NYSE:GMED, NYSE:NVRO, NAS:INGN, NAS:SPNC, NAS:MDXG, NYSE:ITGR, NAS:CNMD, NAS:BABY » details
Traded in other countries:BSX.Germany,
Headquarter Location:USA
Boston Scientific Corp is a developer, manufacturer and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Top Ranked Articles about Boston Scientific Corp

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the HeartLogic™ Heart Failure Diagnostic
Boston Scientific To Participate In Morgan Stanley Global Healthcare Conference
Boston Scientific To Participate In Wells Fargo 2017 Healthcare Conference
Boston Scientific To Participate In 2017 Canaccord Genuity Growth Conference
Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System
Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty
The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year
Julian Robertson Buys Adobe and Sells Apple in 1st Quarter Guru adds 3 positions and closes 3 others
Julian Robertson (Trades, Portfolio), founder of Tiger Management, invests with long-short strategies. During the first quarter, the guru added positions in Adobe Systems Inc. (NASDAQ:ADBE), Boston Scientific Corp. (NYSE:BSX) and JPMorgan Chase & Co. (NYSE:JPM). On the sell side, Robertson divested his holdings in HollyFrontier Corp. (NYSE:HFC), Apple Inc. (NASDAQ:AAPL) and Shire PLC (NASDAQ:SHPG). Read more...
Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage Closure Device
New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints

Ratios

vs
industry
vs
history
PE Ratio 49.46
BSX's PE Ratio is ranked lower than
84% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. BSX: 49.46 )
Ranked among companies with meaningful PE Ratio only.
BSX' s PE Ratio Range Over the Past 10 Years
Min: 13.87  Med: 45.39 Max: 404.33
Current: 49.46
13.87
404.33
Forward PE Ratio 20.88
BSX's Forward PE Ratio is ranked higher than
71% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. BSX: 20.88 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 49.46
BSX's PE Ratio without NRI is ranked lower than
84% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. BSX: 49.46 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87  Med: 45.39 Max: 404.33
Current: 49.46
13.87
404.33
Price-to-Owner-Earnings 36.28
BSX's Price-to-Owner-Earnings is ranked lower than
67% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 36.31 vs. BSX: 36.28 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58  Med: 43.6 Max: 985.26
Current: 36.28
11.58
985.26
PB Ratio 5.43
BSX's PB Ratio is ranked lower than
74% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. BSX: 5.43 )
Ranked among companies with meaningful PB Ratio only.
BSX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.45 Max: 5.49
Current: 5.43
0.59
5.49
PS Ratio 4.54
BSX's PS Ratio is ranked lower than
64% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. BSX: 4.54 )
Ranked among companies with meaningful PS Ratio only.
BSX' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.22 Max: 4.59
Current: 4.54
1.02
4.59
Price-to-Free-Cash-Flow 126.40
BSX's Price-to-Free-Cash-Flow is ranked lower than
81% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. BSX: 126.40 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.21  Med: 21.01 Max: 220
Current: 126.4
7.21
220
Price-to-Operating-Cash-Flow 54.03
BSX's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. BSX: 54.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 16 Max: 62.72
Current: 54.03
5.75
62.72
EV-to-EBIT 46.27
BSX's EV-to-EBIT is ranked lower than
93% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. BSX: 46.27 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2577.3  Med: -3.7 Max: 25838
Current: 46.27
-2577.3
25838
EV-to-EBITDA 29.40
BSX's EV-to-EBITDA is ranked lower than
86% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. BSX: 29.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 9 Max: 242.5
Current: 29.4
-680.1
242.5
EV-to-Revenue 5.16
BSX's EV-to-Revenue is ranked lower than
63% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. BSX: 5.16 )
Ranked among companies with meaningful EV-to-Revenue only.
BSX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 2.9 Max: 5.3
Current: 5.16
1
5.3
Current Ratio 0.75
BSX's Current Ratio is ranked lower than
88% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. BSX: 0.75 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.56 Max: 7.77
Current: 0.75
0.52
7.77
Quick Ratio 0.51
BSX's Quick Ratio is ranked lower than
90% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. BSX: 0.51 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.2 Max: 6.29
Current: 0.51
0.33
6.29
Days Inventory 144.19
BSX's Days Inventory is ranked lower than
55% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. BSX: 144.19 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 113.61  Med: 133.18 Max: 164.78
Current: 144.19
113.61
164.78
Days Sales Outstanding 60.49
BSX's Days Sales Outstanding is ranked higher than
60% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. BSX: 60.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 60.49
58.51
66.79
Days Payable 55.01
BSX's Days Payable is ranked higher than
50% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. BSX: 55.01 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 67.31
Current: 55.01
21.66
67.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. BSX: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.9  Med: -1 Max: 4.6
Current: -1
-25.9
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.07
BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
60% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. BSX: 3.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.51  Med: 1.55 Max: 500
Current: 3.07
0.51
500
Price-to-Median-PS-Value 2.05
BSX's Price-to-Median-PS-Value is ranked lower than
87% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. BSX: 2.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.48 Max: 4.29
Current: 2.05
0.48
4.29
Price-to-Peter-Lynch-Fair-Value 1.62
BSX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. BSX: 1.62 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BSX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.63 Max: 12.18
Current: 1.62
0
12.18
Earnings Yield (Greenblatt) % 2.15
BSX's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. BSX: 2.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.3  Med: -1.3 Max: 9.1
Current: 2.15
-34.3
9.1
Forward Rate of Return (Yacktman) % 42.23
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.78 vs. BSX: 42.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.1  Med: 7 Max: 42.23
Current: 42.23
3.1
42.23

More Statistics

Revenue (TTM) (Mil) $8,713.00
EPS (TTM) $ 0.58
Beta0.97
Short Percentage of Float1.03%
52-Week Range $19.67 - 29.40
Shares Outstanding (Mil)1,372.13

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,904 9,494 10,137
EPS ($) 1.26 1.40 1.53
EPS without NRI ($) 1.26 1.40 1.53
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.20%
Dividends per Share ($)
» More Articles for BSX

Headlines

Articles On GuruFocus.com
Boston Scientific To Participate In Morgan Stanley Global Healthcare Conference Aug 28 2017 
Boston Scientific To Participate In Wells Fargo 2017 Healthcare Conference Aug 21 2017 
Boston Scientific To Participate In 2017 Canaccord Genuity Growth Conference Jul 31 2017 
Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System Jun 06 2017 
Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty May 24 2017 
Goldman Sachs Rates Health Care Stocks May 17 2017 
The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global May 16 2017 
Julian Robertson Buys Adobe and Sells Apple in 1st Quarter May 15 2017 
Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage May 12 2017 
New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Trad May 12 2017 

More From Other Websites
Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the HeartLogic™ Heart... Sep 19 2017
3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific... Sep 12 2017
See what the IHS Markit Score report has to say about Boston Scientific Corp. Sep 12 2017
Stocks Close Mixed; eBay, These Other 5 Top Stocks Hit Buy Points Sep 07 2017
Boston Scientific Grows on Innovation, Buyouts Amid Woes Sep 06 2017
Boston Scientific’s Updated 2017 Guidance Sep 04 2017
Boston Scientific’s Expansion Plans in a Fast-Growing Market Sep 04 2017
Boston Scientific Is Accelerating Category Leadership Strategy Sep 04 2017
How Can BSX Improve Its Profitability Going Forward? Sep 01 2017
Boston Scientific Corp. breached its 50 day moving average in a Bullish Manner : BSX-US : September... Sep 01 2017
Boston Scientific’s Stellar 2Q17 Results: Key Highlights Sep 01 2017
Wall Street’s Upbeat on Boston Scientific: Most Recommend a ‘Buy’ Sep 01 2017
​Boston Scientific receives award at the Pentagon for support of veterans Aug 29 2017
Boston Scientific To Participate In Morgan Stanley Global Healthcare Conference Aug 28 2017
[$$] Medical Tech Bounces Back in Emerging Markets Aug 23 2017
[$$] Funding Snapshot: Women's Health Care Provider Channel Medsystems Receives $14.1 Million Series... Aug 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}